Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: Analysis of efficacy and safety

Annals of Hematology

Volumn 89, Issue 9, 2010, Pages 905-912

  Lee, Sung Sook ^a   Suh, Cheolwon ^b   Kim, Bong Seog ^c   Chung, Jooseop ^d   Joo, Young Don ^e   Ryoo, Hun Mo ^f   Do, Young Rok ^g   Jin, Jong Youl ^h   Kang, Hye Jin ⁱ   Lee, Gyeong Won ^j   Lee, Moon Hee ^k   Shim, Hyeok ^l   Kim, Kihyun ^m   Yoon, Sung Soo ⁿ   Bang, Soo Mee ^o   Kim, Ho Young ^p   Lee, Je Jung ^q   Park, Jinny ^r   Lee, Dong Soon ⁿ   Lee, Jae Hoon ^r  

^a Yonsei University College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

^d Pusan National University Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Catholic University of Daegu   (South Korea)

^g Dongsan Medical Center   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Korea Institute of Radiation and Medical Science   (South Korea)

^j Gyeongsang National University   (South Korea)

^k Inha University Hospital   (South Korea)

^l Wonkwang University Hospital   (South Korea)

^m Samsung Medical Center   (South Korea)

ⁿ Seoul National University College of Medicine   (South Korea)

^o Seoul National University Bundang Hospital   (South Korea)

^p Hallym University Medical Center   (South Korea)

^q Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^r Gachon University College of Medicine   (South Korea)

more..

Author keywords

Bortezomib; Dexamethasone; Doxorubicin; Multiple myeloma; Relapse; Thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; INFECTION; INSOMNIA; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; UREMIA; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; SALVAGE THERAPY; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77955654072     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0943-z     Document Type: Article

References (27)

1. A Glasmacher C Hahn F Hoffmann, et al. 2006 A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma Br J Haematol 132 584 593 10.1111/j.1365-2141.2005. 05914.x 1:CAS:528:DC%2BD28XislCqtb0%3D 16445831 (Pubitemid 43381591)
2. PG Richardson E Blood CS Mitsiades, et al. 2006 A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma Blood 108 3458 3464 10.1182/blood-2006-04-015909 1:CAS:528:DC%2BD28Xht1ahsLzO 16840727
3. PG Richardson P Sonneveld MW Schuster, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D 15958804 (Pubitemid 41007864)
4. J Bladé DH Vesole M Gertz 2003 High-dose therapy in multiple myeloma Blood 102 10 3469 3470 10.1182/blood-2003-01-0073 12893762 (Pubitemid 37409360)
5. SV Raikumar R Fonseca A Dispenzieri, et al. 2000 Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 75 897 901 10.4065/75.9.897
6. S Singhal J Mehta R Desikan, et al. 1999 Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565 1571 10.1056/NEJM199911183412102 1:CAS:528:DyaK1MXotVSgs78%3D 10564685
7. SV Rajkumar S Hayman MA Gertz, et al. 2002 Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 4319 4323 10.1200/JCO.2002.02.116 1:CAS:528:DC%2BD38Xpt1CjtLk%3D 12409330 (Pubitemid 35266292)
8. D Weber K Rankin M Gavino, et al. 2003 Thalidomide alone or with dexamethasone for previously untreated multiple myeloma J Clin Oncol 21 16 19 10.1200/JCO.2003.03.139 1:CAS:528:DC%2BD2cXpsVWru7o%3D 12506164
9. PG Richardson B Barlogie J Berenson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 2617 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D 12826635 (Pubitemid 36741588)
10. PG Richardson P Sonneveld M Schuster, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557 3560 10.1182/blood-2006-08-036947 1:CAS:528: DC%2BD2sXhtlarur3K 17690257 (Pubitemid 350159621)
11. RZ Orlowski A Nagler P Sonneveld, et al. 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 3892 3901 10.1200/JCO.2006.10.5460 1:CAS:528:DC%2BD2sXhtFanu73M 17679727 (Pubitemid 47477266)
12. ED Faith R Noopur H Teru, et al. 2001 Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma Blood 98 210 216 10.1182/blood.V98.1.210
13. T Hideshima D Chauhan Y Shima, et al. 2000 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2943 2950 1:CAS:528:DC%2BD3cXnslGnsbw%3D 11049970
14. B Joan S Diana R Donna, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1115 1123 10.1046/j.1365-2141.1998.00930.x (Pubitemid 28435189)
15. http://ctep.cancer.gov/forms/CTCAE-Index.pdf
16. DM Weber C Chen R Niesvizky, et al. 2007 Multiple myeloma (009) study investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133 2142 10.1056/NEJMoa070596 1:CAS:528:DC%2BD2sXhtlGis7bM 18032763 (Pubitemid 350146108)
17. M Dimopoulos A Spencer M Attal, et al. 2007 Multiple myeloma (010) study investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123 2132 10.1056/NEJMoa070594 1:CAS:528:DC%2BD2sXhtlGis7nN 18032762 (Pubitemid 350146107)
18. S Ciolli F Leoni C Casini, et al. 2008 The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma Br J Haematol 141 6 814 819 10.1111/j.1365-2141.2008.07147.x 1:CAS:528:DC%2BD1cXotlCqsr8%3D 18410447 (Pubitemid 351724874)
19. M Attal JL Harousseau AM Stoppa, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome N Engl J Med 335 91 97 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D 8649495 (Pubitemid 26240110)
20. JA Child GJ Morgan FE Davies Medical Research Council Adult Leukaemia Working Party, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 1883 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D 12736280 (Pubitemid 36532313)
21. B Barlogie G Tricot E Anaissie, et al. 2006 Thalidomide and hematopoietic-cell transplantation for multiple myeloma N Engl J Med 354 1021 1030 10.1056/NEJMoa053583 1:CAS:528:DC%2BD28XitFWluro%3D 16525139 (Pubitemid 43357806)
22. SV Rajkumar A Dispenzieri 2005 Evaluation and monitoring of response to therapy in multiple myeloma Haematologica 90 1305 1308 16219565
23. A Palumbo F Gay S Bringhen, et al. 2008 Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma Ann Oncol 19 1160 1165 10.1093/annonc/mdn018 1:STN:280:DC%2BD1czktlWntg%3D%3D 18326520 (Pubitemid 351796343)
24. BG Durie J Jacobson B Barlogie, et al. 2004 Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials J Clin Oncol 22 1857 1863 10.1200/JCO.2004.05.111 15111617 (Pubitemid 41095176)
25. S Jagannath PG Richardson B Barlogie, et al. 2006 Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone Haematologica 91 929 934 1:CAS:528:DC%2BD28XnslSmsrg%3D 16818280
26. P Sonneveld R Hajek A Nagler DOXIL-MMY-3001 Study Investigators, et al. 2008 Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy Cancer 112 1529 1537 10.1002/cncr.23326 1:CAS:528:DC%2BD1cXktlKrur0%3D 18300257 (Pubitemid 351441165)
27. HE Oakervee R Popat N Curry, et al. 2005 PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 755 762 10.1111/j.1365-2141. 2005.05519.x 1:CAS:528:DC%2BD2MXms1ehs7c%3D 15953001 (Pubitemid 40904525)